We suggest that the clinical efficacy of resveratrol in the treatment of cancer may be restored or potentiated by blocking the cancer cell surface receptor for thyroid hormone in vivo, or by reducing circulating levels of T4 and substituting T3 to maintain euthyroidism (euthyroid hypothyroxinemia) [70]. The gene discussed is CD177; the disease is cancer.